research use only
Cat.No.S9629
| Related Targets | Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES |
|---|---|
| Other Estrogen/progestogen Receptor Inhibitors | Vepdegestrant (ARV-471) MPP dihydrochloride Kaempferol Cholesterol PHTPP G15 Licochalcone A Endoxifen HCl Chrysin Pregnenolone |
|
In vitro |
DMSO
: 100 mg/mL
(188.12 mM)
Water : 25 mg/mL Ethanol : 6 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 531.56 | Formula | C30H40Cl2N2O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1349723-93-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | SMILES | CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
ERα
48 nM
ERβ
870 nM
|
|---|---|
| In vitro |
Elacestrant (RAD1901) Dihydrochloride is a selective estrogen receptor degradation (SERD), which inhibits expression of ERα and ERβ in cultured breast tumor cell lines, thus inhibits the cell proliferation in a dose-dependent manner. |
References |
(data from https://clinicaltrials.gov, updated on 2026-08-07)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07242352 | RECRUITING | Breast Cancer; HR+/HER2- Breast Cancer |
Women's Cancer Study Group GmbH |
2026-04-29 | PHASE3 |
| NCT05512364 | RECRUITING | ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2023-12-15 | PHASE3 |
| NCT07753954 | NOT_YET_RECRUITING | ER+ / HER2- Advanced Breast Cancer |
Jules Bordet Institute |
2026-09-13 | PHASE2 |
| NCT07222215 | RECRUITING | Estrogen-receptor-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2- Breast Cancer; ESR1 Gene Mutation; ER Wildtype; Breast Neoplasms |
Kristina A. Fanucci |
2026-01-16 | PHASE2 |
| NCT06120283 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer |
BeOne Medicines |
2023-12-01 | PHASE1 |
| NCT06492616 | RECRUITING | Breast Cancer |
Stemline Therapeutics, Inc. |
2024-09-27 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.